David Risinger
Stock Analyst at Leerink Partners
(4.53)
# 266
Out of 5,147 analysts
178
Total ratings
67.35%
Success rate
15.24%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Outperform | $305 → $355 | $388.16 | -8.54% | 6 | Feb 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $62.37 | -3.80% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $496.83 | +5.67% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $28.94 | +10.57% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $25.53 | +76.26% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,051.99 | +4.94% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $6.72 | +346.43% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $69.53 | +0.68% | 4 | Oct 14, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $248.43 | -38.41% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $781.67 | +6.69% | 9 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $206 | $232.08 | -11.24% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $23.45 | +194.24% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $12.00 | +33.33% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $34.41 | +27.87% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $61.74 | +147.81% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $18.25 | -45.21% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $55.05 | -14.62% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $26.86 | -59.05% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $148.95 | -38.91% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $27.65 | +73.60% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $7.29 | +407.54% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $190.02 | -7.38% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $14.93 | +7.17% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $13.22 | +240.39% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $5.93 | +490.22% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $26.40 | +55.30% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $131.10 | +32.72% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $46.21 | +10.37% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $33.86 | -76.37% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $123.82 | -28.12% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $13.81 | -78.28% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $30.10 | -46.84% | 9 | Apr 2, 2020 |
Amgen
Feb 4, 2026
Maintains: Outperform
Price Target: $305 → $355
Current: $388.16
Upside: -8.54%
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $62.37
Upside: -3.80%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $496.83
Upside: +5.67%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $28.94
Upside: +10.57%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $25.53
Upside: +76.26%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,051.99
Upside: +4.94%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $6.72
Upside: +346.43%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $69.53
Upside: +0.68%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $248.43
Upside: -38.41%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $781.67
Upside: +6.69%
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $232.08
Upside: -11.24%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $23.45
Upside: +194.24%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $12.00
Upside: +33.33%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $34.41
Upside: +27.87%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $61.74
Upside: +147.81%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $18.25
Upside: -45.21%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $55.05
Upside: -14.62%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $26.86
Upside: -59.05%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $148.95
Upside: -38.91%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $27.65
Upside: +73.60%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $7.29
Upside: +407.54%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $190.02
Upside: -7.38%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $14.93
Upside: +7.17%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $13.22
Upside: +240.39%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $5.93
Upside: +490.22%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $26.40
Upside: +55.30%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $131.10
Upside: +32.72%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $46.21
Upside: +10.37%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $33.86
Upside: -76.37%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $123.82
Upside: -28.12%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $13.81
Upside: -78.28%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $30.10
Upside: -46.84%